Takeda will open a new plant in Singen, Germany that will manufacture the company’s dengue vaccine candidate, TAK-003. Phase III results show the vaccine is effective against the mosquito-borne virus.  The company began construction in 2016 and invested approximately $140 million to build the facility. It will employ as many as 200 people once operational. The plant is currently ready for packaging production and production of the vaccine, once approved.   In a placebo-controlled stud...